Copyright
©The Author(s) 2018.
World J Hepatol. Feb 27, 2018; 10(2): 186-212
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.186
Published online Feb 27, 2018. doi: 10.4254/wjh.v10.i2.186
Table 3 Selected directly acting antiviral agents and host targeting agents in the pipeline[63]
| Drugs name | Company | Target/active site | Phase |
| NS3/4A protease inhibitors | |||
| Vaniprevir (MK-7009) | Merck | Active site/macrocyclic | III |
| Voxilaprevir GS-9857 | Gilead | Active site | III |
| Glecaprevir (ABT-493) | Abbvie | Active site | III |
| IDX21437 | Idenix | Active site | II |
| Sovaprevir (ACH-1625) | Achillion | Active site/macrocyclic? | II |
| Nucleoside analog NS5B polymerase inhibitors (NI) | |||
| MK-3682 (formerly IDX20963) | Merck | Active site | II |
| ACH-3422 | Achillion/Janssen | Active site | II |
| Non- Nucleoside analog NS5B polymerase inhibitors (NNI) | |||
| Beclabuvir (BMS-791325) | Bristol-Myers Squib | NNI site 1/Thumb 1 | III |
| Setrobuvir (ANA598) | Anadys/Roche | NNI site 4?/palm 1 | II |
| NS5A inhibitors | |||
| BMS-824393 | Bristol-Myers Squibb | NS5A protein | II |
| PPI-461 | Presidio | NS5A protein | II |
| PPI-668 | Presidio | NS5A protein | II |
| Pibrentasvir (ABT-530) | Abbvie | NS5A protein | III |
| ACH-2928 | Achillion | NS5A protein | I |
| Ruzasvir (MK-8408) | Merck | NS5A protein | II |
| Host targeting agents | |||
| SCY-635 | Scynexis | Cyclophilin inhibitor | II |
| Miravirsen | Santaris | miRNA122 antisense NA | II |
| RG-101- | Regulus | miRNA122 antisense NA | II |
| TT-0034 | Tacere Therapeutics | RNA interference with HCV | II |
- Citation: Morozov VA, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. World J Hepatol 2018; 10(2): 186-212
- URL: https://www.wjgnet.com/1948-5182/full/v10/i2/186.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i2.186